Browsing: CAR T-cell therapy

Penn Medicine breakthroughs in CAR-T, mRNA therapies highlight why public trust, sustained research funding remain essential for innovation

Gilead to acquire Arcellx for $7.8 billion, strengthening oncology pipeline with anito-cel CAR T-cell therapy.